die Aussichten wesentlich besser, da haben sie Movantik gekauft und mit diesem fast 20 Millionen umsatz erwirtschaftet und Talica in den Markt eingeführt, damals wurde von einem Umsatzwachstum der neuen Medikamenten auf mehr als 150-200 Millionen für 2022 prognostiziert. RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights August 13, 2020 Q2/2020 net revenues of approximately $21 million, up from $1.1 million in Q1/2020 and $1.6 million in Q2/2019, an increase of approximately 1,900% and 1,200%, respectively Completed acquisition of Movantik® from AstraZeneca and secured exclusive control over U.S. commercialization through new royalty-bearing agreement with Daiichi Sankyo -- Talicia® added as an unrestricted branded agent to three major national formularies, providing a strong platform for continued prescription growth -- Entered into binding term sheet with Cosmo Pharmaceuticals for exclusive licensing and manufacturing agreement for multiple products, under which RedHill is set to receive $12 million upfront and up to another $9 million in milestone payments -- Ongoing global COVID-19 Phase 2/3 and U.S. Phase 2 studies with opaganib planned to deliver preliminary data for potential emergency use applications as early as Q4/2020 -- Pivotal Phase 3 study for first-line pulmonary NTM infections with RHB-204, to be funded primarily by Cosmo Pharmaceuticals, planned to be initiated following recent FDA IND clearance -- Cash balance of approximately $56 million as of August 12, 2020, with an additional $12 million anticipated following closing of the agreement with Cosmo Pharmaceuticals Wir haben uns zu lange von den angekündigten Entwicklungen blenden lassen. |